Pembrolizumab. an inhibitor target programmed death 1 (PD-1). was approved into the first line therapy in advanced non-small cell lung cancer (NSCLC). It was a milestone that immune checkpoints drugs have played an important role in the treatment system of NSCLC. https://www.shopwildwestes.shop/product-category/shirts-kids-2/